About FGen
FGen is a Healthcare company based in Basel (Switzerland) founded in 2010, and was acquired by Ginkgo Bioworks in March 2022. Using synthetic biology, non-GMO and directed evolution to engineer proteins, pathways and cells. FGen has raised $28.8 thousand across 2 funding rounds from investors including Ginkgo Bioworks, European Union and Venture Kick. FGen offers products and services including R&D Tools, AI Models, and Lab Automation. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
FGen is a research services company spun-off from the Department of Biosystems Science and Engineering at ETH, Zurich. The company has developed a proprietary nanoliter reactor platform for high-throughput phenotypic analysis of cells, which it combines with synthetic biology, non-GM approaches or directed evolution to develop engineered proteins, pathways or cells. The NLR platform is used for high-throughput, high-content phenotypic screening of cell libraries of bacterial, yeast, fungal or mammalian cells for discovery and scale up of enzymes, biologics, proteins, chemicals, or cells.
- Headquarters Basel, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website fgen.ch
- Social LinkedIn
- Acquired by Ginkgo Bioworks (Mar 2022)
- Total Equity Funding$28.8K (USD)
in 2 rounds
- Latest Funding Round$56K (USD), Grant
May 2019
- InvestorsGinkgo Bioworks
& 2 more
- Acquired byGinkgo Bioworks
(Mar 2022)
Products & Services of FGen
FGen offers a comprehensive portfolio of products and services, including R&D Tools, AI Models, and Lab Automation.
Provides datasets and AI models for research acceleration.
Offers fine-tuning and data generation for biotechnology needs.
Delivers automated systems for efficient lab processes.
Funding Insights of FGen
FGen has successfully raised a total of $28.8K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $56 thousand completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28,800
- Total Rounds 2
- Last Round Grant — $56,002
- First Round $28,800
(Jun 2010)
- Investors Count 2
All 2 funding rounds of FGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $56,002 | Grant | – | – | |
| Jun 2010 | $28,800 | Seed | – | Venture Kick | – |
3 investors in total: 3 institutional.
Investors in FGen
FGen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Ginkgo Bioworks, European Union and Venture Kick.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
University backed startup accelerator | venturekick.ch | Schlieren, Switzerland | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Gene editing-based cultured ingredients are provided for agriculture. | 2008 | ginkgobioworks.com | Boston, United States |
Investor details for FGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of FGen
4 dated milestones of FGen across 12 years, from founding to its latest funding, stage changes and deals.
- Founded FGen is founded.
- Funding First funding round of $29K.
- Funding Latest funding round, Grant, of $56K.
- Exit Acquired by Ginkgo Bioworks.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fgen
Complete news archive for FGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FGen
FGen was founded in 2010.
FGen is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
FGen is a funded company, having raised a total of $28.8K across 2 funding rounds to date. The company's 1st funding round was a Seed of $28.8K, raised on Jun 2010.
FGen is a research services company spun-off from the Department of Biosystems Science and Engineering at ETH, Zurich. The company has developed a proprietary nanoliter reactor platform for high-throughput phenotypic analysis of cells, which it combines with synthetic biology, non-GM approaches or directed evolution to develop engineered proteins, pathways or cells. The NLR platform is used for high-throughput, high-content phenotypic screening of cell libraries of bacterial, yeast, fungal or mammalian cells for discovery and scale up of enzymes, biologics, proteins, chemicals, or cells.
FGen offers R&D Tools, AI Models, and Lab Automation.
FGen has 3 investors. Key investors include Ginkgo Bioworks, European Union, and Venture Kick.
Yes. FGen was acquired by Ginkgo Bioworks in March 2022.